Herpes vaccine candidate tracker
Every HSV (herpes-simplex-virus) vaccine candidate we track, ordered by how far it has progressed. Each row shows the current phase and the date we last verified it. Open a candidate for its full status and sources.
| Candidate | Developer | Platform | Target | Approach | Phase | Updated |
|---|---|---|---|---|---|---|
| HerpV | Agenus | protein subunit | HSV-2 | therapeutic | phase 2 | |
| VCL-HB01 | Vical | DNA | HSV-2 | therapeutic | phase 2 | |
| G103 | Sanofi Pasteur, a Sanofi Company (lead sponsor of NCT04222985) | protein subunit | HSV-2 | therapeutic | phase 1 | |
| HSV529 | Sanofi Pasteur (trials run with NIAID and Fred Hutchinson Cancer Center) | replication-defective live | HSV-2 | both | phase 1 | |
| BCHT HSV-2 mRNA vaccine | Changchun BCHT Biotechnology Co. | mRNA | HSV-2 | unclear | phase 1 | |
| GSK4108771A | GlaxoSmithKline | other | unclear | unclear | phase 1 | |
| pPJV7630 | PowderMed | DNA | HSV-2 | therapeutic | phase 1 | |
| BNT163 | BioNTech SE | mRNA | HSV-2 | prophylactic | phase 1 | |
| Trivalent gC2/gD2/gE2 mRNA (UPenn) | University of Pennsylvania (Friedman & Weissman labs); licensed to BioNTech | mRNA | HSV-2 | prophylactic | preclinical | |
| GEN-003 | Genocea Biosciences | protein subunit | HSV-2 | therapeutic | discontinued | |
| Herpevac (gD2 subunit, GSK) | GlaxoSmithKline | protein subunit | HSV-2 | prophylactic | discontinued | |
| mRNA-1608 | Moderna (ModernaTX, Inc.) | mRNA | HSV-2 | therapeutic | discontinued | |
| Theravax / Profavax (Rational Vaccines) | Rational Vaccines (William Halford) | live-attenuated | both | both | cautionary |